Hence, in addition to blockage of EGFR signaling, Cetuximab induces ADCC and the relevance of NK cells and innate immune system in the anti-cancer efficacy of this antibody has gained intense attention, also with respect to design of novel combination strategies [56–61]. This evidence concerns the gene EGFR and cancer.